DBV Technologies SA logo

DBVT - DBV Technologies SA Share Price

$1.51 0.0  2.7%

Last Trade - 8:25pm

Small Cap
Market Cap £120.3m
Enterprise Value £-14.8m
Revenue £3.26m
Position in Universe 4966th / 7414
Unlock DBVT Revenue
Relative Strength (%)
1m -5.24%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -78.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
6.84 10.0 13.4 17.1 14.7 11.3 8.85 12.9 +10.5%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2021, DBVTechnologies SA revenues decreased 83% to $1.5M. Net lossdecreased 33% to $60.2M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Lower net loss reflectsRestructuring and related costs decrease from $21.3M(expense) to $0K, Research and Development decrease of 14%to $42.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


DBVT Revenue Unlock DBVT Revenue

Net Income

DBVT Net Income Unlock DBVT Revenue

Normalised EPS

DBVT Normalised EPS Unlock DBVT Revenue

PE Ratio Range

DBVT PE Ratio Range Unlock DBVT Revenue

Dividend Yield Range

DBVT Dividend Yield Range Unlock DBVT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2022
31st Dec 2023
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
DBVT EPS Forecasts Unlock DBVT Revenue
Profile Summary

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated March 1, 2002
Public Since March 29, 2012
No. of Shareholders: n/a
No. of Employees: 121
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market (Dual Listing)
Shares in Issue 109,757,498
Free Float (0.0%)
Eligible for
DBVT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for DBVT
Upcoming Events for DBVT
Wednesday 9th March, 2022 Estimate
Full Year 2021 DBV Technologies SA Earnings Release
Thursday 19th May, 2022 Estimate
DBV Technologies SA Annual Shareholders Meeting
Frequently Asked Questions for DBV Technologies SA
What is the DBV Technologies SA share price?

As of 8:25pm, shares in DBV Technologies SA are trading at $1.51, giving the company a market capitalisation of £120.3m. This share price information is delayed by 15 minutes.

How has the DBV Technologies SA share price performed this year?

Shares in DBV Technologies SA are currently trading at $1.51 and the price has moved by -75.21% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the DBV Technologies SA price has moved by -78.27% over the past year.

What are the analyst and broker recommendations for DBV Technologies SA?

Of the analysts with advisory recommendations for DBV Technologies SA, there are there are currently 0 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for DBV Technologies SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will DBV Technologies SA next release its financial results?

DBV Technologies SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the DBV Technologies SA dividend yield?

DBV Technologies SA does not currently pay a dividend.

Does DBV Technologies SA pay a dividend?

DBV Technologies SA does not currently pay a dividend.

When does DBV Technologies SA next pay dividends?

DBV Technologies SA does not currently pay a dividend.

How do I buy DBV Technologies SA shares?

To buy shares in DBV Technologies SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of DBV Technologies SA?

Shares in DBV Technologies SA are currently trading at $1.51, giving the company a market capitalisation of £120.3m.

Where are DBV Technologies SA shares listed? Where are DBV Technologies SA shares listed?

Here are the trading details for DBV Technologies SA:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: DBVT
What kind of share is DBV Technologies SA?

Based on an overall assessment of its quality, value and momentum, DBV Technologies SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a DBV Technologies SA share price forecast 2022?

Shares in DBV Technologies SA are currently priced at $1.51. At that level they are trading at 0.17% discount to the analyst consensus target price of 0.00.

Analysts covering DBV Technologies SA currently have a consensus Earnings Per Share (EPS) forecast of -1.3281879 for the next financial year.

How can I tell whether the DBV Technologies SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DBV Technologies SA. Over the past six months, the relative strength of its shares against the market has been -74.44%. At the current price of $1.51, shares in DBV Technologies SA are trading at -67.89% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the DBV Technologies SA PE Ratio?

We were not able to find PE ratio data for DBV Technologies SA.

Who are the key directors of DBV Technologies SA?

DBV Technologies SA's management team is headed by:

Mailys Ferrere - NED
Michel de Rosen - NEC
Daniel Tasse - CEO
Pharis Mohideen - OTH
Julie O'Neill - NED
Michael Goller - NED
Sebastien Robitaille - CFO
Michele Robertson - OTH
Adora Ndu - IND
Who are the major shareholders of DBV Technologies SA?

Here are the top five shareholders of DBV Technologies SA based on the size of their shareholding:

Baker Bros. Advisors LP Hedge Fund
Percentage owned: 13.28% (14.6m shares)
Perceptive Advisors LLC Private Equity
Percentage owned: 6.99% (7.70m shares)
Boxer Capital, L.L.C. Hedge Fund
Percentage owned: 6.85% (7.53m shares)
ArrowMark Colorado Holdings, LLC Investment Advisor/Hedge Fund
Percentage owned: 1.3% (1.44m shares)
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund
Percentage owned: 1.16% (1.27m shares)
Similar to DBVT
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.